Italy Tests Groundbreaking Therapy Against Aggressive Glioblastoma

Italian research is developing an unprecedented precision therapy against glioblastoma, one of the most aggressive and poorest-prognosis brain tumors. The project, named TEPOV, is led by Giovanni Marfia from the University of Milan and was selected by the European Research Council (ERC) within the 2026 Starting Grants, according to ANSA.

What is the TEPOV project

TEPOV was created with the goal of tackling one of oncology's greatest challenges: glioblastoma, a brain tumor known for its high capacity to resist conventional treatments and its rapid, aggressive progression. According to ANSA, the research is coordinated by Giovanni Marfia from the University of Milan and seeks to develop a precision therapy approach capable of acting directly on the biological mechanisms that make this type of tumor so lethal.

The project was selected by the European Research Council (ERC) in the 2026 edition of Starting Grants, one of Europe's most competitive funding opportunities for cutting-edge scientific research. ERC support is aimed at researchers proposing innovative investigations with potential to generate significant advances in their fields — in TEPOV's case, neuro-oncology.

Anyone following Italy News knows that the country has stood out in recent years for high-impact biomedical research investments, and ERC recognition reinforces Italian scientific leadership on the European stage.

The role of AND-C4 medication

At the center of the TEPOV project's therapeutic strategy is AND-C4, a monoclonal antibody developed by Milan-based biotech Andremacon S.r.l. According to ANSA, the compound has already received Orphan Drug Designation from the regulatory agency, recognition granted to substances intended for treating rare or therapeutically difficult-to-manage diseases.

The mechanism of action of AND-C4 is what sets this research apart from traditional approaches against glioblastoma. Rather than directly attacking tumor cells as conventional chemotherapies do, the therapy acts on a specific erythropoietin variant, identified as EV-3, which appears to be related to tumor aggressiveness. The scientific proposal is to reprogram the biological behavior of tumor cells, reducing their capacity for growth and spread.

This approach fits within a broader movement in global oncology toward precision medicine, which seeks treatments directed at specific molecular targets, with potential to reduce side effects and increase efficacy against historically resistant tumors like glioblastoma.

Why it matters to descendants of Italians

For the Italian-Brazilian community, news like this goes beyond scientific interest: it is a source of pride and reconnection with contemporary Italy, a country that combines tradition and innovation. The prominence of Italian universities, like Milan's, in cutting-edge medical research reinforces Italy's image as a relevant pole of science and technology in Europe — an aspect rarely explored by those who associate the country only with history and gastronomy.

Beyond symbolic value, there is a practical dimension that interests everyone: advances like TEPOV have the potential to, in time, benefit patients in various parts of the world, including Brazil, should the therapy progress through the necessary clinical and regulatory phases before reaching broader medical use.

Those living or planning to live in Italy, whether for work, study, or through Italian citizenship, also closely follow this type of development, as the country's healthcare system and research infrastructure are part of the daily life of those who settle there. For Brazilians of Italian descent seeking information about life in the country, the portal brings together content about daily life through the Life in Italy section.

Those with Italian citizenship recognition processes underway and depending on historical documentation can still turn to specialized services in certificate searches in Italy, while more complex cases typically rely on support from a specialized Italian citizenship consulting firm.

The advancement of research like TEPOV shows that Italy continues to invest in high-level science, with potential impact that transcends borders — and reinforces, for descendants of Italians around the world, ties with a country that continues to produce knowledge relevant to global health.

Source: ANSA